EuCorVac-19 vaccine gets greenlight for trials

송경선 2021. 1. 21. 19:24
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

닫기
The Ministry of Food and Drug Safety granted the go-ahead for Eubiologics to start Phase 1 and 2 clinical trials for its Covid-19 vaccine candidate on Wednesday, making it the fifth Korean bio firm to receive the approval.

The Ministry of Food and Drug Safety granted the go-ahead for Eubiologics to start Phase 1 and 2 clinical trials for its Covid-19 vaccine candidate on Wednesday, making it the fifth Korean bio firm to receive the approval.

Phase 1 clinical trials will be conducted on healthy adults to test the substance’s safety and the level of antibodies it could create in the human body.

The Eubiologics vaccine candidate, EuCorVac-19, delivers immune boosters in liposomes, which are like nano-sized spheres. It is a recombinant vaccine made with genetic recombination technology. The surface antigen of the vaccine stimulates the immune cell to produce neutralizing antibodies to fight the Covid-19 virus.

As of Wednesday, seven vaccine candidates and 15 coronavirus treatment candidates are undergoing clinical trials in Korea.

BY SONG KYOUNG-SON [song.kyoungson@joongang.co.kr]

Copyright © 코리아중앙데일리. 무단전재 및 재배포 금지.